Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigen‐Specific Therapy for Experimental Autoimmune Encephalomyelitis (Adv. Mater. 5/2022)

Metabolic Glycoengineering Immune checkpoint ligand functionalized Schwann cells have great potential to treat multiple sclerosis. In article number 2107392, Kin Man Au, Andrew Z. Wang, and Roland Tisch bioengineer Schwann cells functionalized with programmed death ligand 1 (PD‐L1) and cluster of di...

Full description

Saved in:
Bibliographic Details
Published in:Advanced materials (Weinheim) 2022-02, Vol.34 (5), p.n/a
Main Authors: Au, Kin Man, Tisch, Roland, Wang, Andrew Z.
Format: Article
Language:English
Subjects:
Antigens
Bioengineering
bioorthogonal click chemistry
Encephalomyelitis
experimental autoimmune encephalomyelitis
immune checkpoint
Ligands
Lymphocytes
Materials science
metabolic glycoengineering
Multiple sclerosis
Schwann cells
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic Glycoengineering Immune checkpoint ligand functionalized Schwann cells have great potential to treat multiple sclerosis. In article number 2107392, Kin Man Au, Andrew Z. Wang, and Roland Tisch bioengineer Schwann cells functionalized with programmed death ligand 1 (PD‐L1) and cluster of differentiation 86 (CD86) to prevent and ameliorate established mouse models of chronic and relapsing–remitting experimental autoimmune encephalomyelitis by promoting the development of tolerogenic neuroantigen‐specific regulatory T cells.
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.202270039